Related Experiment Video
Updated: Jun 12, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
The Complexity of Malignant Glioma Treatment
Linde F C Kampers1, Dennis S Metselaar2,3,4,5, Maria Vinci6
1Immun-Onkologisches Zentrum Köln, 50674 Köln, Germany.
Abstract:
Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
Insights
Malignant glioma, a deadly brain cancer, is driven by five key hallmarks within its unique tumor microenvironment. Future treatments should combine therapies targeting these hallmarks and the tumor microenvironment for better outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Tumor Microenvironment Research
Background:
- Malignant glioma is an aggressive brain tumor with poor therapeutic response.
- The tumor microenvironment (TME) significantly influences glioma development and resistance.
- Five cancer hallmarks are particularly crucial in malignant glioma: GSCs, vascularization/hypoxia, metabolic reprogramming, inflammation, and proliferation.
Purpose of the Study:
- To review the critical cancer hallmarks implicated in malignant glioma.
- To highlight the role of the tumor microenvironment in driving glioma progression.
- To propose a combined therapeutic strategy for malignant glioma.
Main Methods:
- Literature review of cancer hallmarks and TME in malignant glioma.
- Analysis of the interplay between hallmarks and TME.
- Identification of potential therapeutic targets and strategies.
Main Results:
- Five specific cancer hallmarks (GSCs, vascularization/hypoxia, metabolic reprogramming, inflammation, proliferation) are central to malignant glioma.
- The TME critically mediates the interactions between these hallmarks.
- Malignant glioma exhibits spatio-temporal heterogeneity driven by TME interactions.
Conclusions:
- A multimodal therapeutic approach is necessary to overcome malignant glioma's complexity.
- Combining anticancer therapies, repurposed drugs, and immunotherapy targeting hallmarks and TME is a promising future direction.
- Addressing the TME and its driven hallmarks is essential for improving malignant glioma treatment outcomes.
